Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
15 avr. 2024 08h00 HE
|
Pulmocide, Ltd.
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse...
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h00 HE
|
Pulmocide, Ltd.
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering from serious acute and chronic...
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole
16 oct. 2023 08h00 HE
|
Pulmocide, Ltd.
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Announces Expansion of Management Team
08 juin 2023 07h00 HE
|
Pulmocide, Ltd.
LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
06 déc. 2022 07h00 HE
|
Pulmocide, Ltd.
LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Receives Investment from the Cystic Fibrosis Foundation
06 déc. 2021 08h00 HE
|
Pulmocide, Ltd.
The Cystic Fibrosis Foundation invested $3.5 million in Pulmocide as part of the CF Foundation’s Lung Transplant InitiativeFunding supports prophylaxis study in lung transplant patients LONDON,...